论文信息 - Inherited variants in XRCC2 and the risk of breast cancer - 字舞流文

Inherited variants in XRCC2 and the risk of breast cancer

A. Jakubowska | J. Lubiński | S. Narod | C. Szczylik | R. Kordek | A. Mackiewicz | S. Góźdź | C. Cybulski | D. Wokołorczyk | W. Kluźniak | M. Akbari | P. Domagała | T. Byrski | T. Huzarski | J. Gronwald | T. Dębniak | M. Lener | B. Górski | O. Haus | S. Gozdecka-Grodecka | M. Szwiec | J. Mituś | D. Surdyka | H. Janiszewska | E. Kilar | M. Bębenek | J. Sir | Z. Morawiec | S. Niepsuj | B. Kozak-Klonowska | B. Waśko | R. Wiśniowski | A. Synowiec | Maryam Bagherzadeh | D. Godlewski | H. Rudnicka | Agata Szymiczek | A. Kashyap | M. Jasiówka | M. Siołek | R. Sibilski | M. Cechowska | J. Jarkiewicz-Tretyn | Bogna Rusak | Klaudia Stempa | J. Tomiczek-Szwiec | M. D. S. S. O. H. M. E. R. B. G. A. E. J. Z. S. R. M. Bębenek Godlewski Gozdecka-Grodecka Goźdź Haus | G. Książkiewicz | E. Marczak | R. Uciński | B. Kozak‐Klonowska

[1] A. Jakubowska,et al. The spectrum of mutations predisposing to familial breast cancer in Poland , 2019, International journal of cancer.

[2] M. Bihoreau,et al. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing , 2018, International journal of cancer.

[3] F. Mancuso,et al. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings , 2018, Journal of Cancer Research and Clinical Oncology.

[4] J. Gardovskis,et al. High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population , 2018, Hereditary Cancer in Clinical Practice.

[5] Nina Ditsch,et al. Gene panel testing of 5589 BRCA1/2‐negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer , 2018, Cancer medicine.

[6] Sitao Wu,et al. Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing , 2019, JAMA oncology.

[7] E. Ostrander,et al. Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks , 2017, Journal of Medical Genetics.

[8] P. Devilee,et al. Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility Gene XRCC2 , 2016, Human mutation.

[9] A. Jankowska,et al. Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene , 2016, Journal of Medical Genetics.

[10] Nazneen Rahman,et al. Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.

[11] A. Jakubowska,et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. , 2015, The Lancet. Oncology.

[12] Aniruddh Kashyap,et al. Germline RECQL mutations are associated with breast cancer susceptibility , 2015, Nature Genetics.

[13] A. Jakubowska,et al. Recurrent mutations of BRCA1 and BRCA2 in Poland: an update , 2015, Clinical genetics.

[14] Tina Pesaran,et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients , 2014, Genetics in Medicine.

[15] Yuya Kobayashi,et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16] F. Couch,et al. Rare variants in XRCC2 as breast cancer susceptibility alleles , 2012, Journal of Medical Genetics.

[17] Daniel J. Park,et al. Rare mutations in XRCC2 increase the risk of breast cancer. , 2012, American journal of human genetics.

[18] A. Jakubowska,et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19] Dieter Niederacher,et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.

[20] J. Satagopan,et al. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. , 2007, Cancer research.

[21] A. Jakubowska,et al. NBS1 Is a Prostate Cancer Susceptibility Gene , 2004, Cancer Research.

[22] S. Scherer,et al. The XRCC2 DNA repair gene: identification of a positional candidate. , 1997, Genomics.

[23] Julian Peto,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[24] D. Bentley,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[25] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[26] J. Benítez,et al. Rare Mutations in XRCC 2 Increase the Risk of Breast Cancer , 2022 .